JOAO DE QUEVEDO: Open Payments
NPI 1205231008 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,214 in 55 payments from 14 companies in 2025. Trend: 2023 $30,608 · 2024 $2,867 · 2025 $2,214
Food & beverage: $2,214
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $788 |
| Neurocrine BioSciences, Inc. | 6 | $339 |
| LivaNova USA, Inc. | 5 | $276 |
| Janssen Pharmaceuticals, Inc | 3 | $191 |
| Janssen Scientific Affairs, LLC | 1 | $135 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Abbott Laboratories | 1 | $90 |
| Axsome Therapeutics, Inc. | 1 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $47 |
Products named: CAPLYTA, SPRAVATO, VNS THERAPY SYMMETRY MODEL 8103 GENERATOR, INGREZZA, REXULTI, INFINITY, Auvelity, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
